Obrixtamig
- Generic Name
- Obrixtamig
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Conditions
- Neuroendocrine Neoplasms
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT06132113
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT05990738
- Locations
- 🇺🇸
Mayo Clinic - Florida, Jacksonville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇫🇷INS Curie, Paris, France
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
- Conditions
- Neuroendocrine NeoplasmsSmall Cell Lung Carcinoma (SCLC)
- Interventions
- Drug: [89Zr]Zr-BI 764532
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT05963867
- Locations
- 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT05916313
- Locations
- 🇦🇹
Salzburg Cancer Research Institute, Salzburg, Austria
🇩🇪Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Tübingen, Tübingen, Germany
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- Conditions
- Neuroendocrine NeoplasmsSmall Cell Lung Carcinoma (SCLC)
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT05879978
- Locations
- 🇫🇷
INS Claudius Regaud IUCT-Oncopole, Toulouse, France
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇫🇷CTR François Baclesse, Caen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.